Nuvectis Pharma (NASDAQ:NVCT) Hits New 1-Year High – What’s Next?

Posted by Francis Steltz on Jun 26th, 2026

Nuvectis Pharma, Inc. (NASDAQ:NVCT – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $19.67 and last traded at $19.9390, with a volume of 102743 shares changing hands. The stock had previously closed at $17.55.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nuvectis Pharma in a research note on Friday, June 5th. Wall Street Zen raised shares of Nuvectis Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, HC Wainwright increased their target price on shares of Nuvectis Pharma from $13.00 to $39.00 and gave the company a “buy” rating in a research report on Monday. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $39.00.

View Our Latest Report on NVCT

Nuvectis Pharma Stock Up 13.8%

The firm has a market capitalization of $739.39 million, a price-to-earnings ratio of -21.27 and a beta of -0.07. The company’s 50 day moving average price is $11.09 and its 200 day moving average price is $9.28.

Nuvectis Pharma (NASDAQ:NVCT – Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.04. As a group, analysts expect that Nuvectis Pharma, Inc. will post -1.01 earnings per share for the current year.

Institutional Investors Weigh In On Nuvectis Pharma

A number of institutional investors and hedge funds have recently modified their holdings of NVCT. Vanguard Group Inc. boosted its position in Nuvectis Pharma by 4.8% in the third quarter. Vanguard Group Inc. now owns 698,708 shares of the company’s stock valued at $4,206,000 after buying an additional 31,903 shares during the last quarter. Iridian Asset Management LLC CT lifted its stake in Nuvectis Pharma by 44.5% during the 4th quarter. Iridian Asset Management LLC CT now owns 586,320 shares of the company’s stock valued at $4,427,000 after acquiring an additional 180,699 shares during the period. Baldwin Wealth Partners LLC MA lifted its stake in Nuvectis Pharma by 11.2% during the 4th quarter. Baldwin Wealth Partners LLC MA now owns 389,625 shares of the company’s stock valued at $2,942,000 after acquiring an additional 39,164 shares during the period. Occam Crest Management LP boosted its holdings in shares of Nuvectis Pharma by 31.0% in the 4th quarter. Occam Crest Management LP now owns 380,000 shares of the company’s stock valued at $2,869,000 after acquiring an additional 90,000 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Nuvectis Pharma by 11.8% in the 4th quarter. Geode Capital Management LLC now owns 364,024 shares of the company’s stock valued at $2,749,000 after acquiring an additional 38,291 shares during the last quarter. Institutional investors and hedge funds own 96.77% of the company’s stock.

About Nuvectis Pharma

(Get Free Report)

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.